Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease.

Sánchez-Ortega, Isabel

Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease. [electronic resource] - Croatian medical journal Jun 2016 - 247-54 p. digital

Publication Type: Journal Article

1332-8166

10.3325/cmj.2016.57.247 doi


Adult
Aged
Antineoplastic Agents--administration & dosage
Dasatinib--administration & dosage
Female
Graft vs Host Disease
Humans
Imatinib Mesylate--administration & dosage
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--therapy
Male
Middle Aged
Retrospective Studies
Salvage Therapy
Sclerosis--complications
Treatment Outcome